South Korea is one of the most active life science markets in the world. In 2019, USD 806.7m was invested in Korean private biotech companies that accounted for almost 4% of the total global biotech financing amount. The country currently offers hundreds of biotech and medtech assets to out-licence.
We would like to thank our partner Seoul BioHub operated by KHIDI (Korea Health Industry Development Institute) for their significant help with creating the report.
Would you like to be notified about new reports and other valuable content published by Biotechgate?